China-based WuXi Biologics (HKG: 2269) delivered a speech at the J.P. Morgan Healthcare Conference, where its chief executive officer (CEO) Chen Zhisheng outlined the company’s strategic direction and achievements. Despite negative global macroeconomic conditions and inclusion on the US unverified list, WuXi Biologics has maintained its business model and continued to expand its operations.
Program Expansion and Commercial Achievements
In 2022, WuXi Biologics added 137 new comprehensive programs, bringing its total to 588, including 11 programs transferred externally. The company has successfully brought 17 projects through to commercialization. Its monoclonal antibodies (mAbs) targeting FcRn and TIGIT, as well as bispecific antibodies (BsAbs), are expected to enter late-stage clinical and commercialization stages imminently. These advancements highlight WuXi Biologics’ commitment to innovation and delivering value to its clients.
Manufacturing and Regulatory Strengths
WuXi Biologics boasted a 262,000-liter manufacturing capacity in 2022, with 14 plants in China, Germany, and Ireland, all aligned with Good Manufacturing Practice (GMP) standards. The company has also passed 27 inspections by more than 10 drug regulatory bodies worldwide, underscoring its robust compliance and quality control measures.
Future Outlook
Chen Zhisheng’s remarks at the J.P. Morgan Healthcare Conference reaffirmed WuXi Biologics’ dedication to its current business model, emphasizing the company’s resilience and adaptability in the face of global challenges. With a strong pipeline and significant manufacturing capacity, WuXi Biologics is well-positioned to continue its growth trajectory and support the development of next-generation therapies.-Fineline Info & Tech
